We initiate our coverage on genetic products maker Affymetrix (AFFX) with a Neutral recommendation. The company posted respectable results in fourth-quarter fiscal 2010 with earnings beating the Zacks Consensus Estimate while profit surged 42% year over year as lower costs more than offset a decline in sales. California-based Affymetrix is a leading provider of microarray-based [...] (AFFX) Affymetrix Analyst Initiates Shares at Neutral